北陸藥業(300016.SZ)半日漲6.21% 參股公司涉阿爾茲海默症相關產品
格隆匯11月4日丨北陸藥業(300016.SZ)半日收漲6.21%,報9.23元,成交1.26億元,最新總市值45.13億元。

週末醫藥行業迎來重磅利好,全球17年來首款阿爾茲海默症新藥獲批。
國家藥品監督管理局批准治療阿爾茨海默病原創新藥甘露特鈉膠囊(GV-971)上市,這也是上海試點藥品上市許可持有人制度(MAH)、推動創新研發成果快速上市的成功案例。業內人士表示,該藥的獲批上市,填補了過去17年AD治療領域無新藥上市的空白,為廣大飽受阿爾茨海默病困擾的患者帶來“福音”。
而北陸藥業參股銥磑醫療,銥磑醫療核心產品腦醫生(Dr.Brain)雲平台是專注於中樞神經系統疾病的一站式人工智能診斷及分析平台,已開發上線了針對阿爾茲海默症、帕金森症、腦卒中等多種中樞神經系統疾病的產品矩陣,在全國近百家三甲醫院成功落地。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.